Gianrico Farrugia, M.D.
Director, Center for Individualized Medicine, Mayo Clinic
Dr. Farrugia completed his undergraduate training at St. Aloysius College in Birkirkara, Malta, and his M.D. at the University of Malta Medical School in 1987. He is a consultant in the Division of Gastroenterology and Hepatology and the Department of Physiology and Biomedical Engineering at Mayo Clinic in Rochester, Minn., as well as a professor of medicine and physiology in the Mayo Clinic College of Medicine. He is the director of the Mayo Clinic Center for Individualized Medicine.
Dr. Farrugia is the basic science editor of the journal Neurogastroenterology & Motility. His research interests include genomics, the treatment of disorders of gastrointestinal motility, mechanosensitive ion channels, ion channel regulation, and a cell type known as the interstitial cell of Cajal. He has published more than 250 articles on these topics.
Dr. Farrugia's awards include top teacher awards, the Outstanding Investigator Award from the Mayo Clinic Department of Internal Medicine, and the Janssen Award for Outstanding Science in Gastroenterology.
Managing Director, Health Research Institute, PwC
Ms. Connolly is managing director of the Health Research Institute at PwC, where she oversees a team of analysts and writers tracking trends and developments across the health care industry.
Ms. Connolly is a veteran journalist, author and commentator who spent 25 years reporting on national politics, health care, Latin America and natural disasters, including Hurricane Katrina. She has appeared on PBS' "Washington Week," CBS' "The Early Show," NPR's "The Diane Rehm Show," and several news programs on MSNBC and Fox News Channel. She's spoken at the prestigious National Press Club, the Chautauqua Institution, the Cleveland Clinic, and at numerous universities and health care conferences.
As national health correspondent for The Washington Post, she chronicled the enactment of the Affordable Care Act and was co-author of "Landmark: The Inside Story of America's New Health Care Law and What It Means for Us All."
Ms. Connolly is a board member of the nonprofit Whitman-Walker Health and is the first nonphysician to receive Mayo Clinic's Plummer Society Award for Excellence for promoting deeper understanding of science and medicine. She serves on the National Advisory Committee of the Center for Sustainable Health Spending and was the recipient of a fellowship at Harvard's Kennedy School of Government.
Before joining PwC, Ms. Connolly was a senior adviser at the McKinsey Center for U.S. Health System Reform.
Michael J. Ackerman, M.D., Ph.D.
Consultant, Division of Cardiovascular Diseases, Mayo Clinic
Dr. Ackerman, of Mayo Clinic in Rochester, Minn., is the Windland Smith Rice Cardiovascular Genomics Research Professor and a professor of medicine, pediatrics and pharmacology at Mayo Clinic College of Medicine.
As director of Mayo Clinic's Long QT Syndrome/Genetic Heart Rhythm Clinic and the Windland Smith Rice Sudden Death Genomics Laboratory, Dr. Ackerman strives to fulfill the twofold objective of medical education and biomedical research as stated by Dr. Charles H. Mayo: "to heal the sick and to advance the science."
He has published more than 400 articles and chapters across the continuum of basic, translational and clinical research with a focus on cardiac channelopathies, hypertrophic cardiomyopathy and sudden cardiac death in the young.
Dr. Ackerman received his M.D. and Ph.D. from Mayo Medical School and Mayo Graduate School and completed pediatric and pediatric cardiology training at Mayo School of Graduate Medical Education. Dr. Ackerman is president of the Sudden Arrhythmia Death Syndromes (SADS) Foundation.
Erich J. Baker, Ph.D.
Director of Bioinformatics, Baylor University
Dr. Baker is an associate professor and director of bioinformatics at Baylor University. Before joining the faculty at Baylor in 2002, he served as a postdoctoral research associate at Oak Ridge National Laboratory in the Genome Annotation and System Modeling Group.
Dr. Baker's research interests include the application of emerging database techniques, data management and data analytic strategies for the discovery of knowledge in complex genomic landscapes. This includes the harmonization of distributed biological data sources and data types using graph-based data integration.
His approach to distributed data analysis has served as the foundation for several distributed genomics analysis efforts, including MouseTrack and the Shewanella Knowledge System. Currently, he serves as the lead bioinformatics investigator for the Monkey Alcohol Tissue Research Resource and GeneWeaver, a Web-based system for large-scale functional genomics analysis.
Diana W. Bianchi, M.D.
Executive Director, Mother Infant Research Institute, Tufts Medical Center
Dr. Bianchi is the executive director of the Mother Infant Research Institute at Tufts Medical Center and the Natalie V. Zucker Professor of Pediatrics, Obstetrics and Gynecology at Tufts University School of Medicine. She is also vice chair for pediatric research at the Floating Hospital for Children in Boston.
Dr. Bianchi received her M.D. from Stanford University School of Medicine, then completed residency training in pediatrics at Boston Children's Hospital and postdoctoral fellowship training in both medical genetics and neonatal-perinatal medicine at Harvard University. She is board certified in all three specialties and is a practicing medical geneticist with special expertise in reproductive genetics.
Her translational research focuses on prenatal genomics with the goal of advancing noninvasive prenatal DNA diagnosis and using information from fetal gene expression to develop new fetal therapies.
Dr. Bianchi has published more than 250 peer-reviewed articles, and is one of four authors of the book "Fetology: Diagnosis and Management of the Fetal Patient." This book won the Association of American Publishers award for best textbook in clinical medicine in 2000. The second edition was published in April 2010 and is already in its third printing. It has been translated into Japanese, Mandarin and Spanish.
Dr. Bianchi is recognized locally, nationally and internationally for her leadership roles. She is editor-in-chief of the international journal Prenatal Diagnosis. She is a member of the National Advisory Council of the Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD) and is a past president of the International Society for Prenatal Diagnosis and the Perinatal Research Society.
She has received multiple awards, including the Duane Alexander Award for leadership and mentorship in perinatal medicine from the NICHD, and the Christopher Columbus Celebrate Discovery Award and the Distinguished Faculty Award, both from Tufts University. In 2013, she was elected to the Institute of Medicine.
Judy C. Boughey, M.D.
Consultant, Division of Subspecialty General Surgery, Mayo Clinic
Dr. Boughey is a consultant in the Division of Subspecialty General Surgery at Mayo Clinic in Rochester, Minn., and a professor of surgery at Mayo Clinic College of Medicine. She is also program director of the Mayo Clinic Multidisciplinary Breast Surgery Fellowship and chair of the Committee on Education of the American College of Surgeons Clinical Research Program.
Dr. Boughey is actively involved with clinical trial development in the Alliance for Clinical Trials in Oncology and sits on the Breast Oncology Local Disease Task Force, a National Cancer Institute advisory committee.
She is the national principal investigator of several clinical trials. These include ACOSOG-Z1071, which evaluated the role of sentinel lymph node surgery after neoadjuvant chemotherapy in women presenting with node-positive breast cancer; Alliance A11202, comparing radiation and axillary dissection for local control in patients with node-positive disease after chemotherapy; and Alliance Z11102, evaluating breast conservation for women with multiple ipsilateral breast cancers.
Dr. Boughey is co-principal investigator with Matthew P. Goetz, M.D., of the Breast Cancer Genome Guided Therapy (BEAUTY) Study, a major initiative of the Mayo Clinic Center of Individualized Medicine and Mayo Clinic Cancer Center. This study compares genomic information from breast cancers prior to chemotherapy and during chemotherapy and residual disease after chemotherapy in 150 women with high-risk breast cancer and develops patient-derived xenografts prior to and after chemotherapy, working to identify new drugs and individualize the approach to breast cancer therapy.
Dr. Boughey is chair of the Division of Surgery Research, vice chair for research for the Department of Surgery, and medical director of the Surgical Clinical Research Office at Mayo Clinic in Rochester.
Lon Cardon, Ph.D.
Head of Alternative Discovery and Development, GlaxoSmithKline
Dr. Cardon joined GlaxoSmithKline in 2008, initially as head of Genetics. He is now head of Alternative Discovery and Development, a pan-therapeutic division focused on nontraditional approaches for drug discovery and development.
The unit takes on new diseases for GlaxoSmithKline, such as ophthalmology and rare diseases; new modalities, including gene therapy, stem cells and oligonucleotides; and bespoke academic and biotechnology partnership models.
Before joining GlaxoSmithKline, Dr. Cardon was a senior academic in the U.K. and U.S., as professor of bioinformatics at the University of Oxford until 2006 and then as professor of biostatistics at the University of Washington and Fred Hutchinson Cancer Research Center in Seattle.
He received his Ph.D. training from the Institute for Behavioral Genetics at the University of Colorado and conducted his postdoctoral research in the Department of Mathematics at Stanford University. He has received a number of scientific awards, including election to the U.K.'s Academy of Medical Sciences in 2005. He has authored more than 200 scientific publications and 15 books and chapters.
Elizabeth C. Chao, M.D.
Medical Director, Ambry Genetics, and Assistant Professor, University of California, Irvine
Dr. Chao received her M.D. from the University of California, Irvine, and trained as a Howard Hughes Scholar at the National Human Genome Research Institute, specializing in genomic technologies and cancer genetics.
Dr. Chao further completed her clinical training in genetics at The Children's Hospital of Philadelphia and then served as associate director of the Genetic Diagnostic Lab at the University of Pennsylvania.
Her research has focused on novel methods for interpreting DNA variants. Dr. Chao is the author of MAPP-MMR, a novel algorithm for variant classification in Lynch syndrome.
Dr. Chao has served as medical director at Ambry Genetics since 2011, leading the development team for Ambry's next-generation sequencing-based hereditary cancer tests, the launch of whole-exome sequencing, and the implementation of a robust variant classification program based on multifactorial analysis. This continues to be the focus of Dr. Chao's research at the University of California, Irvine, where she directs the Molecular Genetics Laboratory and works to improve the integration of genomic testing into patient care.
John Connolly, Ph.D.
Neuropsychologist, Center for Applied Genomics, Children's Hospital of Philadelphia
Dr. Connolly is a neuropsychologist as well as communications and education manager at the Center for Applied Genomics of the Children's Hospital of Philadelphia. He established and maintains the Center for Applied Genomics' online presence and manages its education policy under the Electronic Medical Records and Genomics (eMERGE) consortium. In addition, he maintains an active presence in neurogenomics research.
Dr. Connolly played a key role in managing the Philadelphia Neurodevelopment Cohort, a joint effort with the University of Pennsylvania that merges deep neurobehavioral phenotypes with medical records and genotype data.
He previously led development of Genes to Cognition Online at Cold Spring Harbor Laboratory, creating an online resource that examines how the brain, biochemicals and genes interact to produce neuropsychiatric disorders such as autism, ADHD, depression and schizophrenia. He also managed development of 3D Brain, an award-winning smartphone application that has been downloaded more than 2 million times.
He trained as neuropsychologist at Trinity College Dublin, where he studied stroke rehabilitation and neural correlates of attention-deficit/hyperactivity disorders.
Christopher L. Corless, M.D., Ph.D.
Professor of Pathology, Oregon Health & Science University
After undergraduate studies at the University of California, Berkeley, Dr. Corless received his M.D. and Ph.D. degrees from Washington University in St. Louis. He did his residency training in anatomic pathology at Brigham and Women's Hospital in Boston, where he also completed fellowship training in gastrointestinal pathology and genitourinary pathology.
In 1994, he joined the faculty of Oregon Health & Science University (OHSU) as an assistant professor. He has served as the residency program director in pathology and medical director of surgical pathology for OHSU Hospital.
Dr. Corless is an associate director of the Oregon Clinical & Translational Research Institute and serves as chief medical officer for the OHSU Knight Diagnostic Laboratories. In addition to practicing surgical pathology, Dr. Corless has expertise in the application of molecular diagnostics to the classification and prognostication of solid tumors. He was promoted to professor of pathology in 2004 and is an author on more than 200 publications.
David P. Dimmock, M.D.
Medical College of Wisconsin
Ahmet Dogan, M.D., Ph.D.
Chief of the Hematopathology Service, Departments of Pathology and Laboratory Medicine, Memorial Sloan Kettering Cancer Center
Dr. Dogan is a board-certified pathologist and an internationally recognized leader in hematopathology, the branch of pathology concerned with diseases of the blood and of hematopoietic and lymphoid tissue.
Dr. Dogan's current research interests include lymphoma, plasma cell disorders, and diagnostic techniques for hematopathology such as cytogenetic analysis, genomics and proteomics. His previous work has contributed much to the understanding of the histogenesis of lymphomas, MALT lymphomas and T cell lymphomas in particular.
As hematopathology service chief, Dr. Dogan is responsible for orchestrating the integration of diagnostic results across multiple laboratories to enhance patient care and for helping to foster increased primary and collaborative research related to hematologic malignancies treated at Memorial Sloan Kettering Cancer Center.
Before joining Memorial Sloan Kettering, Dr. Dogan was a professor of laboratory medicine and pathology at Mayo Clinic in Rochester, Minn., where he also served as an attending consultant pathologist, medical director of immunostains and the clinical proteomics laboratory, and vice chair of the Division of Anatomic Pathology.
Before that, he spent four years as an attending pathologist and professor of hematopathology at University College London. Dr. Dogan was actively involved in the education and training of residents and fellows at University College London and developed a new curriculum and accompanying textbook in pathology for undergraduate medical students.
Stephanie Malia Fullerton, D.Phil.
Director, Institute for Public Health Genetics, and Associate Professor of Bioethics and Humanities, University of Washington
Dr. Fullerton is an associate professor of bioethics and humanities at the University of Washington School of Medicine and director of the Institute for Public Health Genetics in the Department of Biostatistics at the University of Washington School of Public Health.
She is also an adjunct associate professor in the University of Washington departments of Epidemiology and Genome Sciences, as well as an affiliate investigator with the Public Health Sciences division of the Fred Hutchinson Cancer Research Center.
She received a Ph.D. in human population genetics from the University of Oxford and later retrained in ethical, legal and social implications research, with a fellowship from the National Human Genome Research Institute.
Dr. Fullerton's work focuses on the ethical and social implications of genetics and genomics research, including researcher and participant perspectives on data sharing, secondary use and result return. She is also interested in scientists' understandings of human genetic variation and its relation to disease risk, the use of racial and ethnic constructs in the conduct and interpretation of genetic research, and the responsible incorporation of genomic methodologies into broader programs of health disparities research.
She currently serves as a co-investigator with the Center for Genomics and Healthcare Equality and directs the Ethics and Policy Core of the Partnership to Understand and Eliminate Disparate Outcomes in Latinas Center at the Fred Hutchinson Cancer Research Center.
In addition, she co-directs the Ethical and Psychosocial Implications Research component of the NEXT Medicine study and serves as a co-investigator with the Group Health/University of Washington Electronic Medical Records and Genomics (eMERGE) Network project.
Chairman of the Board and CEO, Florida Blue
Mr. Geraghty is chairman of the board of directors and CEO of Florida Blue, the state's largest health plan serving more than 7 million people in Florida and providing Medicare payment services to beneficiaries across 15 other states.
Throughout his career, Mr. Geraghty has been active in community and professional organizations. He is a member of United Way's Board of Trustees and, in 2011, was appointed to the Florida Council of 100. In addition, Mr. Geraghty chaired the Minnesota chapter of CEOs Against Cancer and was selected the National CEO of the Year for 2011 by the American Cancer Society.
Throughout his career, Mr. Geraghty has been active in community and professional organizations. He is a member of United Way's Board of Trustees and, in 2011, was appointed to the Florida Council of 100. In addition, Mr. Geraghty chaired the Minnesota chapter of CEOs Against Cancer and was selected the National CEO of the Year for 2011 by the American Cancer Society.
Mr. Geraghty frequently speaks on a range of health care topics, including the impact of health care reform, payment reform strategies, innovation in health care, and prevention and wellness. He has appeared on NBC's "Meet the Press," MSNBC's "Morning Joe," Bloomberg TV's "Street Smart" and "Capitol Gains," Wall Street Journal's "Money Beat," Fox Business News, and "PBS Nightly Business Report."
Additionally, Mr. Geraghty has been featured in the The Wall Street Journal, The New York Times, The Florida Times Union, Miami Herald, The Tampa Tribune, Tampa Bay Times and Orlando Sentinel, among other publications.
Richard A. Gibbs, Ph.D.
Director, Human Genome Sequencing Center, Baylor College of Medicine
Dr. Gibbs was born in Australia and graduated from Melbourne University and the Peter MacCallum Cancer Institute in 1986. Dr. Gibbs then moved to the U.S., where he performed key work on the molecular characterization of human genetic disease and the development of methods for mutation detection.
He provided an early leadership role for the Human Genome Project and in 1997 founded the Baylor College of Medicine Human Genome Sequencing Center in Houston. Under his leadership, the center was one of five main groups to complete the Human Genome Project and since has completed the genomes of many other species. The Human Genome Sequencing Center now employs approximately 200 staff, with 25 Ph.D. researchers.
Subsequently, the group has both contributed to major international large-scale genetics projects and focused on the analysis of individual personal human genomes, including the Watson, Tutu and Lupski genome projects. In 2007, the Human Genome Sequencing Center began to systematically analyze genes and genomes involved in somatic mutations in cancer. Since then, the group has been a major data producer for the national cancer genome programs.
Dr. Gibbs' group has been a major force in developing the entire field of genomics and has led efforts to use genomics in medicine. In 2011, the Human Genome Sequencing Center collaborated with the Department of Human and Molecular Genetics at Baylor College of Medicine to create the first genetics diagnostics laboratory based on whole-gene sequencing. This has been tremendously successful and has grown so that more than 200 families a month are now receiving clinical data from complete gene sequencing.
Dr. Gibbs served on the advisory council of the National Institutes of Health's National Human Genome Research Institute and has been the recipient of several awards and prizes. He was elected to the Institute of Medicine in 2011, named an honorary fellow of the Royal College of Pathologists of Australasia in 2011, and recognized as one of the 400 most influential biomedical scientists in the world in 2013 by the European Journal of Clinical Investigation.
At Baylor College of Medicine, Dr. Gibbs holds the rank and title of the Wofford Cain Distinguished Professor of Molecular and Human Genetics and is the director of the Human Genome Sequencing Center.
Geoffrey S. Ginsburg, M.D., Ph.D.
Founding Director for Genomic Medicine, Duke Institute for Genome Sciences & Policy, and Founding Executive Director of the Center for Personalized Medicine, Duke University Health System
Dr. Ginsburg is the founding director for Genomic Medicine in the Duke Institute for Genome Sciences & Policy and the founding executive director of the Center for Personalized Medicine in the Duke University Health System. He is a professor of medicine, pathology and biomedical engineering at Duke University.
He is an internationally recognized expert in genomics and personalized medicine with funding from the National Institutes of Health, Department of Defense, Air Force, Defense Advanced Research Projects Agency, the Gates Foundation and industry.
Prior to Duke, he was at Millennium Pharmaceuticals Inc., where he was vice president of Molecular and Personalized Medicine and responsible for developing pharmacogenomic and biomarker strategies for therapeutics.
He serves as an expert panel member for Genome Canada; as a member of the Board of External Experts for the National Heart, Lung, and Blood Institute; as co-chair of the Institute of Medicine's Roundtable on Translating Genomic-Based Research for Health; as a member of the advisory council for the National Center for Advancing Translational Sciences; as co-chair of the Cures Acceleration Network; as an expert adviser to the Pharmacogenomics Research Network; and as a member of the World Economics Forum's Global Agenda Council on Personalized and Precision Health Care.
Matthew P. Goetz, M.D.
Consultant, Division of Medical Oncology, Mayo Clinic
Dr. Goetz is a consultant in the Division of Medical Oncology at Mayo Clinic in Rochester, Minn., and a professor of oncology and associate professor of pharmacology at Mayo Clinic College of Medicine.
He is chair of the Mayo Clinic Breast Cancer Disease-Oriented Group, co-leader of the Mayo Clinic Women's Cancer Program, and deputy director of the Mayo Clinic Breast Cancer SPORE.
Dr. Goetz has been the lead investigator in translational studies regarding integration of pharmacogenomics into clinical oncology. His seminal work regarding the pharmacogenomics of tamoxifen identified the tamoxifen metabolite, endoxifen, as a critical determinant of tamoxifen efficacy in the treatment of postmenopausal breast cancer.
From these discoveries, Dr. Goetz has led a collaboration between the National Cancer Institute and Mayo Clinic to develop a novel formulation of endoxifen for the hormonal treatment of breast cancer, resulting in multiple National Cancer Institute-sponsored studies to evaluate the safety and efficacy of endoxifen.
Dr. Goetz is co-principal investigator with Judy C. Boughey, M.D., of the Breast Cancer Genome Guided Therapy (BEAUTY) Study, a major initiative of the Mayo Clinic Center for Individualized Medicine and Mayo Clinic Cancer Center. This study is designed to comprehensively assess the genomic landscape of breast cancers before and after neoadjuvant chemotherapy as well as immortalize breast cancers at both time points (xenografts). The overarching goal is to identify novel markers of resistance and identify new drug targets for patients at highest risk of treatment failure.
Aaron J. Goldenberg, Ph.D.
Case Western Reserve University
Jill Hagenkord, M.D.
Chief Medical Officer, 23andMe
Dr. Hagenkord joined 23andMe in 2014 and serves as chief medical officer, where she is responsible for all medical-affairs activities, serving as the company liaison to physician, medical, genetics and research industry groups. She also oversees laboratory, shipping and fulfillment operations for the company.
Previously, Dr. Hagenkord served as senior vice president of medical strategy for Invitae, a genetics information company, where her role included serving as medical director, contributing to corporate strategy, acting as commercial liaison and leading the company's physician education programs.
Dr. Hagenkord is a board-certified molecular genetic pathologist. Prior to joining Invitae, she served as chief medical officer and senior vice president at Complete Genomics Inc. Her other prior experiences include founder and chief medical officer for iKaryos Diagnostics, associate professor of pathology at Creighton University School of Medicine, director of molecular pathology and clinical genomics at Creighton Medical Laboratories, and pathologist at Deltagen Inc.
Dr. Hagenkord received her M.D. from Stanford University School of Medicine in 1999. She did her residency training in pathology at the University of California, San Francisco, and The University of Iowa, and completed fellowships in pathology/oncology informatics and molecular genetic pathology at the University of Pittsburgh Medical Center.
Paul J. Hergenrother, Ph.D.
Kenneth L. Rinehart Jr. Endowed Chair in Natural Products Chemistry, University of Illinois at Urbana-Champaign
Dr. Hergenrother has been at the University of Illinois since 2001, where he is currently the Kenneth L. Rinehart Jr. Endowed Chair in Natural Products Chemistry. Previously, he was an American Cancer Society postdoctoral fellow in the laboratory of Stuart L. Schreiber, Ph.D., at Harvard University (1999-2001) and a graduate student at The University of Texas at Austin (1994-1999).
Since establishing his own laboratory, Dr. Hergenrother and his team have sought to use small molecules to define novel targets for the treatment of disease, with an emphasis on cancer and multidrug-resistant bacteria.
Dr. Hergenrother's lab discovered the first compound (called PAC-1) to directly activate procaspase-3; PAC-1 has been utilized by many laboratories as a tool for studying procaspase-3 activation and is rapidly moving toward a human clinical trial for the treatment of brain cancers. Dr. Hergenrother's laboratory also discovered the potent anti-cancer activity of the natural product deoxynyboquinone (DNQ) and has demonstrated the tremendous selectivity of DNQ for cancer cells.
Recently, his laboratory reported a novel method for the rapid construction of complex and diverse compounds starting from natural products. The hundreds of compounds they have synthesized through this method will no doubt serve as the starting point for future biological discoveries from Dr. Hergenrother's laboratory and its many collaborators.
James M. Hoffman, M.S., Pharm.D.
Associate Member in Pharmaceutical Sciences and Medication Outcomes and Safety Officer, St. Jude Children's Research Hospital
Dr. Hoffman is an associate member in Pharmaceutical Sciences and the medication outcomes and safety officer at St. Jude Children's Research Hospital in Memphis, Tenn. He earned both his undergraduate and doctoral degrees from the Philadelphia College of Pharmacy at the University of the Sciences in Philadelphia.
He completed an M.S. degree at the University of Wisconsin-Madison and postgraduate training at the University of Wisconsin Hospital and Clinics. He is also an associate professor at the University of Tennessee College of Pharmacy.
Dr. Hoffman leads medication use safety efforts across St. Jude, where patients with catastrophic diseases routinely require complex and high-risk medications. His primary interests include patient safety event detection, clinical decision support and the clinical implementation of pharmacogenetics.
He is an investigator on PG4KDS, which is St. Jude's effort to implement pre-emptive pharmacogenetics. Recent efforts have focused on the development and implementation of active clinical decision support for pharmacogenetics.
Dr. Hoffman has been a member of the Clinical Pharmacogenetics Implementation Consortium (CPIC) since its inception. In 2013, along with colleagues from Mayo Clinic and Stanford University, he expanded CPIC's focus on the integration of pharmacogenetics into the electronic health record by forming an informatics working group within CPIC.
Clifford A. Hudis, M.D.
Chief, Breast Cancer Medicine Service, Memorial Sloan Kettering Cancer Center
Dr. Hudis is chief of the Breast Cancer Medicine Service and attending physician at Memorial Sloan Kettering Cancer Center in New York City, where he is also a professor of medicine at the Weill Cornell Medical College of Cornell University.
He is co-leader of the Breast Disease Management Team at Memorial Sloan Kettering Cancer Center, co-chair of the Breast Committee of the Alliance for Clinical Trials in Oncology (formerly Cancer and Leukemia Group), chair of the Scientific Advisory Committee of the Breast Cancer Research Foundation, a former associate editor of the Journal of Clinical Oncology, and the current president of the American Society of Clinical Oncology.
Dr. Hudis received his Bachelor of Arts from Lehigh University and his M.D. from the Medical College of Pennsylvania in 1983 following the completion of a six-year combined B.A. and M.D. program.
From 1983 through 1987, he trained in internal medicine at the Medical College of Pennsylvania and served as chief medical resident. His hematology-oncology training was completed at Memorial Sloan Kettering Cancer Center in 1991 and since then, he has been a member of the Breast Cancer Medicine Service at Memorial Hospital, becoming chief in 1998.
Dr. Hudis' research interests include drug development with a particular focus on the integration of newer agents into the treatment plan for patients with early-stage disease.
For more than a decade, his research focus has been on the interplay of inflammation, obesity and cancer. With his colleagues, he has described low-grade, chronic white adipose inflammation within the breasts of most overweight and obese women and demonstrated that inflammatory mediators activate the enzyme aromatase, providing a plausible explanation for the increased rates of postmenopausal hormone receptor positive breast cancers associated with increased body mass indices.
His current projects address the role of obesity and inflammation in other common cancers and explore potential interventions.
Peter A. Jones, Ph.D., D.Sc.
Research Director and Chief Scientific Officer, Van Andel Research Institute
Dr. Jones is Van Andel Research Institute's research director and chief scientific officer. He also serves as a distinguished professor and as head of the institute's Laboratory for Cancer Epigenomics. He was born in South Africa, raised and attended college in Rhodesia (now Zimbabwe), and received his Ph.D. from the University of London.
Dr. Jones joined The University of Southern California (USC) in 1977, attaining the rank of professor in 1985 and distinguished professor in 1999, and he was director of the USC Norris Comprehensive Cancer Center between 1993 and 2011.
His laboratory discovered the effects of 5-azacytidine on DNA methylation and linked this process to the activation of silenced genes. Dr. Jones is known for his studies on the molecular biology of cancer and of basic mechanisms of DNA methylation and its role in cancer and differentiation.
Dr. Jones is a past president of the American Association for Cancer Research (AACR) and was elected as a fellow of the AACR Academy in 2013. He has published more than 300 scientific papers and received several honors, including the Outstanding Investigator Grant from the National Cancer Institute. He shared with Stephen Baylin, M.D., the Kirk A. Landon-AACR Prize for Basic Cancer Research from the AACR in 2009 and the Medal of Honor from the American Cancer Society in 2011.
Eric W. Klee, Ph.D.
Associate Consultant, Department of Health Sciences Research, Mayo Clinic
Dr. Klee is an assistant professor of medical informatics and a Bioinformatics Program faculty member in the Department of Health Sciences Research at Mayo Clinic in Rochester, Minn., which he joined in 2005. Dr. Klee is also a co-director and bioinformatics lead of Mayo Clinic's Clinical Genome Sequencing Laboratory and a member of the Department of Laboratory Medicine and Pathology, a position held since 2012.
He earned his Bachelor of Science degree in electrical engineering at Iowa State University in 1997 and obtained a Master of Science degree in health informatics with a focus in bioinformatics at the University of Minnesota in Minneapolis. He went on to complete his Ph.D. in health informatics and bioinformatics at the University of Minnesota in 2005.
Dr. Klee's research is focused on the application of next-generation sequencing for clinical testing and diagnostics. His work includes the translation of emerging bioinformatics methods from the research domain into clinical practice. He is actively involved in the development and implementation of systems to support sequence analysis and interpretation in the context of individualized, precision medicine.
Michael Kolodziej, M.D.
National Medical Director for Oncology Solutions, Office of the Chief Medical Officer, Aetna
Dr. Kolodziej is the national medical director for Oncology Solutions at the Office of the Chief Medical Officer at Aetna. Dr. Kolodziej attended college and medical school at Washington University in St. Louis, where he was Phi Beta Kappa and Alpha Omega Alpha.
He completed internal medicine and hematology-oncology training at the University of Pennsylvania in Philadelphia. After completing training, Dr. Kolodziej joined the faculty at The University of Oklahoma School of Medicine, where he was an associate professor. He joined New York Oncology Hematology in the winter of 1998 and was a partner in the practice until December 2012.
Dr. Kolodziej was an active member of the U.S. Oncology Network Pharmacy and Therapeutics Committee, on the executive committee from 2002 to 2011, and chairman from 2004 to 2011. He served as medical director for oncology services for U.S. Oncology from 2007 to 2011. In this role, he helped direct the implementation of the U.S. Oncology clinical pathways initiative, the integration of the U.S. Oncology electronic medical record into this program, and the development of the U.S. Oncology disease management and advanced care planning programs, now known as Innovent Oncology.
He has published several manuscripts and given several presentations on the cost of cancer care, oncology reimbursement reform and use of evidence-based treatment to enhance value. He is a fellow of the American College of Physicians and a member of the board of the Personalized Medicine Coalition. Dr. Kolodziej is married to Regina Resta, M.D., also a medical oncologist with New York Oncology Hematology, and they have two children, Peter and Katherine.
Teresa M. Kruisselbrink, M.S., CGC
Genetic Counselor, Mayo Clinic
Ms. Kruisselbrink is a certified genetic counselor and supervisor in the Center for Individualized Medicine at Mayo Clinic's campus in Rochester, Minn. In this role, she and her team collaborate to integrate new genomic medicine into education, research and clinical practice across Mayo Clinic's three campuses.
Ms. Kruisselbrink currently provides genetic counseling services within the Division of Cardiovascular Diseases. She has integrated the clinical genetic counseling service model into four distinct areas, including hereditary cardiomyopathies, arrhythmias, amyloidosis and aortopathies.
Her research collaborations include advancing tools to provide customized genetic testing detection rates for patients with hypertrophic cardiomyopathy, and understanding patients' health behavior changes when presented with a personalized genetic-based risk of heart attack.
Ms. Kruisselbrink began her career in 1997 at Mayo Clinic by establishing the role of the laboratory-based genetic counselor in molecular genetics, biochemical genetics, cytogenetics and maternal serum screening. She has provided genetic counseling in medical genetics, neurology, obstetrics, cardiology and outreach clinics.
Ms. Kruisselbrink contributes to numerous educational programs, including Mayo Medical School, Mayo Graduate School, and fellowship and residency programs in the laboratory and clinical environments. She is also actively involved in mentoring high school and college students wishing to pursue careers in genetic counseling. She has created a laboratory-based genetic counseling internship and served as program director through Mayo School of Health Sciences. She has also served as a past vice president for the Minnesota Genetic Counseling Society.
Ms. Kruisselbrink received her B.S. in molecular, cellular, developmental biology and genetics and M.S. in genetic counseling from the University of Minnesota. She is an instructor of laboratory medicine and pathology in Mayo Clinic College of Medicine.
Iftikhar J. Kullo, M.D.
Consultant, Division of Cardiovascular Diseases, Mayo Clinic
Dr. Kullo completed medical school training in Kashmir, India, followed by residency (internal medicine) and fellowship (cardiovascular diseases) training at Mayo Clinic in Rochester, Minn., where he is currently a consultant in the Division of Cardiovascular Diseases and a professor of medicine at the Mayo Clinic College of Medicine.
His clinical areas of interest include uncommon arteriopathies, including early-onset atherosclerosis and aortic aneurysm and dissection syndromes. He directs the Early Atherosclerosis Clinic at Mayo Clinic in Rochester.
Dr. Kullo's research focus is on translational cardiovascular genetics. His work encompasses both discovery of novel genetic variants influencing disease susceptibility and drug response as well as implementation of genomics using the electronic health record.
Dr. Kullo is the principal investigator, with Christopher G. Chute, M.D., Dr. P.H., of the Mayo electronic medical records and genomics (eMERGE) grant. He is also the lead investigator of the Myocardial Infarction Genes (MI-GENES) study, a randomized clinical trial of communicating genomic information to individuals at intermediate risk of coronary heart disease.
Mike Lawrence, Ph.D.
Member, Cancer Genome Analysis Group, Broad Institute
Dr. Lawrence is a member of the Cancer Genome Analysis team, led by Gaddy Getz, Ph.D., at the Broad Institute. His interests lie in statistical methods for identifying a complete list of the genes and pathways that drive cancer, and in developing new ways of visualizing and communicating these datasets effectively to speed new discoveries from high-throughput sequencing into the clinic.
Dr. Lawrence's previous work was in biochemistry (Ph.D. with David Bartel, Ph.D., at MIT on catalytic RNA) and chemical biology (postdoctoral training with David Liu, Ph.D., at Harvard on supercharging protein surfaces).
Lawrence J. Lesko, Ph.D., F.C.P.
Clinical Professor and Director, Center for Pharmacometrics and Systems Pharmacology, University of Florida
Dr. Lesko is clinical professor and director of the Center for Pharmacometrics and Systems Pharmacology (CPSP) at the University of Florida in Orlando. The CPSP is one of the largest academic organizations in the U.S. dedicated to quantitative modeling and simulation and molecular pathway analysis for evaluating benefits and risks of medicines in the context of drug development and regulatory science.
The overall mission of the CPSP is to increase the success rate of early-phase clinical trials of new medicines and advance individualization of drug therapy for new and approved therapies.
Dr. Lesko assumed his current position in July 2011 after having served for 16 years as director of the Office of Clinical Pharmacology in the Center for Drug Evaluation and Research at the Food and Drug Administration (FDA). While at the FDA, Dr. Lesko led regulatory initiatives to advance therapeutic individualization through genetically guided drug selection and drug dosing, particularly through the update of package inserts of previously approved drugs for which new genetic information became available.
He was one of the leading authors of significant guidance for industry, including "Clinical Pharmacogenomics: Premarketing Evaluation in Early Phase Clinical Studies" and "Pharmacogenomics Data Submissions."
Dr. Lesko has published more than 200 peer-reviewed manuscripts, many of which deal with individualization of drug therapy. He has received the Gary Neil Prize for Innovation in Drug Development (2011) and the Rawls-Palmer Progress in Medicine Award (2007) from the American Society for Clinical Pharmacology and Therapeutics (ASCPT), the Scientific Leadership Award for Personalized Medicine (2010) from the Coriell Institute for Medical Research, and the Clinical Service Award (2007) from the University of North Carolina Institute for Pharmacogenomics and Individualized Therapy.
Jennifer B. McCormick, Ph.D.
Associate Consultant, Division of General Internal Medicine, Mayo Clinic
Dr. McCormick joined the departments of Internal Medicine and Health Sciences Research at Mayo Clinic in 2008. She was recruited to Mayo Clinic to assist with the development and enhancement of the Center for Clinical and Translational Science (known then as the Center for Translational Science Activities) Research Ethics Resource, including educational offerings in research ethics, and science and public policy.
In this capacity, she directs Mayo Clinic's Responsible Conduct of Research course and provides lectures on research ethics, social responsibility and policy in other courses. Dr. McCormick is also a consultant on Mayo Clinic's Research Ethics Consultation Service, working closely with the Institutional Review Board (IRB) and the research subject advocate to consider human participant research issues, including how best to protect participant privacy and confidentiality in this age of genomic medicine.
Much of her work focuses on empirical studies aimed at enhancing human participation in research and operationalizing the concepts of professionalism and social responsibility in biomedical research. Dr. McCormick has had a continued interest in genetic research and biobanking, policy implications of data sharing, challenges to protecting participants' privacy and confidentiality, and ethical complexities presented by translating genomic research findings into clinical and public health domains.
She currently leads some of the biomedical ethics activities for the Mayo Clinic Center for Individualized Medicine, serving as a discussion moderator for the center's Community Advisory Board and working with center leaders in the planning and implementation processes for the Mayo Clinic Individualized Medicine Clinic.
Dr. McCormick received her doctorate in molecular cellular biology and master's in public policy from the University of Michigan. She was a Center of Excellence in ELSI Research training fellow at the Stanford Center for Biomedical Ethics before joining Mayo Clinic.
Rebecca Nagy, M.S., CGC
Clinical Associate Professor of Internal Medicine, Wexner Medical Center, The Ohio State University
Ms. Nagy is a certified genetic counselor and clinical associate professor of internal medicine at The Ohio State University's Wexner Medical Center in Columbus, Ohio. She cares for patients and families with inherited cancer syndromes and has specific expertise in the genetics of endocrine neoplasias.
She is an active member of The Ohio State University's Thyroid Cancer Unit and is a co-principal investigator on two National Cancer Institute-funded grants studying the genetics of thyroid cancer. Ms. Nagy is the immediate past president of the National Society of Genetic Counselors.
Barbara Nelsen, Ph.D., MBA
Founder, Nelsen Biomedical
Dr. Nelsen is the founder of Nelsen Biomedical, a strategy consulting firm serving the life sciences industry. She brings more than 20 years of experience working in research and development, business, and strategic development within the biotechnology and pharmaceutical industries, and holds a Ph.D. in molecular biology and an MBA.
Dr. Nelsen has extensive experience in licensing of academic-based technology, developing the business model and business plan, and successfully developing strategic partnerships and funding for early-stage technologies and companies.
In addition, her firm provides due diligence expertise to a number of clients in the venture capital community and market expansion strategies for large global life science firms. She has strong networks in institutions, industry and the investment community.
Previously in her career, Dr. Nelsen was a partner in Northern Lights Seed Fund. Prior to this, she designed the strategic plan for a major restructuring of the University of Minnesota's Office for Technology Commercialization, which she subsequently joined to lead the turnaround. She has held positions as the associate director of business development for MGI Pharma and as director of the Cancer Therapeutics Group at the Austin Institute in Melbourne, Australia.
She is an active investor individually and as part of the Sofia Angel Fund. She is also an adviser to startups at iPROPEL, the Minnesota Angel Network, the Venture Center at the University of Minnesota and Boston University. She frequently speaks at events on entrepreneurship, building startups and virtual companies, and funding. She recently published an article, "Beyond Venture Capital," on funding for entrepreneurs.
Grzegorz S. Nowakowski, M.D.
Consultant, Division of Hematology, Mayo Clinic
Dr. Nowakowski is a consultant and chair of education in the Division of Hematology at Mayo Clinic's campus in Rochester, Minn. He is also an assistant professor of medicine in Mayo Clinic College of Medicine and program director of the Hematology/Oncology Fellowship in Mayo School of Graduate Medical Education.
Dr. Nowakowski received his M.D. from the Medical University of Warsaw, Poland. He completed his internal medicine residency at Norwalk Hospital in Norwalk, Conn., and his fellowship in hematology-oncology at Mayo Clinic in Rochester, Minn. Dr. Nowakowski joined the Mayo Clinic lymphoma group in 2006 as a Mayo Foundation Scholar.
Dr. Nowakowski's research focuses on molecular classification, biology and novel therapies of lymphoproliferative disorders. Dr. Nowakowski is the principal investigator of multiple investigator-initiated and cooperative group clinical trials. He also serves as scientific officer in the Academic and Community Cancer Research United (ACCRU), where he is responsible for overseeing hematology clinical trials.
Dr. Nowakowski is an alumnus of the American Society of Hematology (ASH) Clinical Research Training Institute. He served as a member of the ASH Committee on Scientific Affairs. He also chairs the American Society of Clinical Oncology Lymphoma and Myeloma Education Committee for 2014-2015.
Alexander S. Parker, Ph.D.
Cecilia and Dan Carmichael Family Associate Director, Center for Individualized Medicine, Mayo Clinic in Florida, and Vice Chair, Department of Health Sciences Research, Mayo Clinic in Florida
Dr. Parker is the Cecelia and Dan Carmichael Family Associate Director of the Center for Individualized Medicine at Mayo Clinic in Florida. In addition, he is vice chair of the Department of Health Sciences Research and an associate professor of epidemiology and urology at Mayo Clinic College of Medicine.
Dr. Parker received his master's degree in preventive medicine and his Ph.D. in epidemiology from the University of Iowa. He completed a National Institutes of Health fellowship in genetic epidemiology at Mayo Clinic in Rochester, Minn., in 2003, and joined the staff at Mayo Clinic in Florida in 2004 as the first epidemiologist on the Florida campus.
Dr. Parker's primary area of interest is advancing our understanding of the causes of and treatments for genitourinary cancers, with a particular focus on identifying and developing clinically relevant biomarkers to enhance diagnosis and prognosis of kidney cancer.
He has chaired several national study section panels and currently serves as the principal investigator on five extramural grants, including funding from the National Institutes of Health, the National Cancer Institute, the Department of Defense, the state of Florida, and the James and Esther King Biomedical Research Program.
Dr. Parker was integral in establishing the Individualized Medicine Clinic at Mayo Clinic in Florida, where physicians and scientists are working together to bring exciting new genomic and other technologies to the patient bedside.
Gloria M. Petersen, Ph.D.
Consultant, Department of Health Sciences Research, Mayo Clinic
Dr. Petersen is associate director for Population Sciences in the Mayo Clinic Cancer Center and a professor of epidemiology at Mayo Clinic College of Medicine. She holds the Purvis and Roberta Tabor Professorship at Mayo Clinic.
She obtained her Ph.D. from the University of California, Los Angeles, followed by postdoctoral training in medical genetics at Harbor-UCLA Medical Center. She is a board-certified Ph.D. medical geneticist and a founding fellow of the American College of Medical Genetics.
Dr. Petersen's career includes appointments at UCLA School of Medicine and Cedars-Sinai Medical Center, the Department of Epidemiology at Johns Hopkins University in Baltimore, and the Department of Health Sciences Research at Mayo Clinic in Rochester, Minn., where she also holds joint appointments in medicine and medical genetics.
She is principal investigator of several National Cancer Institute grants, including the Pancreatic Cancer Genetic Epidemiology Consortium, the Mayo Clinic Specialized Program of Research Excellence (SPORE) in Pancreatic Cancer, and the bioethics-focused Genomic Incidental Findings Disclosure, as well as the postdoctoral Mayo Clinic Cancer Genetic Epidemiology Training Program.
Dr. Petersen's research focuses on the genetic and molecular epidemiology of pancreatic cancer, with the goal of improving risk stratification using family history and other risk factors, and early detection targeted to high-risk families and individuals with recent-onset diabetes.
Munir Pirmohamed, M.B., Ch.B., Ph.D.
David Weatherall Chair in Medicine, University of Liverpool
Dr. Pirmohamed is the David Weatherall Chair in Medicine at the University of Liverpool and a consultant physician at Royal Liverpool University Hospital. He holds the only NHS Chair of Pharmacogenetics in the U.K., is deputy director of the Medical Research Council Centre for Drug Safety Science and is director of the Wolfson Centre for Personalised Medicine.
He is also an inaugural National Institute for Health Research senior investigator and a fellow of the Academy of Medical Sciences in the U.K. He has authored more than 300 peer-reviewed publications.
Dr. Pirmohamed's research focuses on individual variability in drug response, both safety and efficacy, with a view to evaluating the mechanisms and identifying strategies to personalize health care in order to optimize drug efficacy and minimize toxicity.
The work spans the whole spectrum from discovery to implementation with laboratory-based studies being linked translationally to patient studies, with the aim being to develop the evidence base that can move discoveries from the lab to the clinic, and from clinic to application.
Dr. Pirmohamed has received a number of honors, including most recently the William Withering Medal from the Royal College of Physicians and the Institute for Pharmacogenomics and Individualized Therapy (IPIT) Award for Public Service from the University of North Carolina.
Dan M. Roden, M.D.
Assistant Vice Chancellor for Personalized Medicine and Professor of Medicine, Vanderbilt University Medical Center
Dr. Roden received his medical degree and training in internal medicine from McGill University in Montreal and trained in clinical pharmacology and cardiology at Vanderbilt University, where he has been a faculty member since.
His initial career focus, which he has maintained, was studies of the clinical, genetic, cellular and molecular basis of arrhythmia susceptibility and variability responses to arrhythmia therapies. Over the last 10 years, Dr. Roden has led Vanderbilt's broader efforts in pharmacogenomics discovery and implementation.
Dr. Roden is principal investigator for the Vanderbilt sites of the National Institutes of Health's Pharmacogenomics Research Network (PGRN) and the National Human Genome Research Institute's Electronic Medical Records and Genomics (eMERGE) Network.
He directs the Vanderbilt DNA databank BioVU, a discovery resource that as of February 2014 included more than 175,000 samples linked to deidentified electronic medical records. He is a leader in the PREDICT project that since 2010 has pre-emptively embedded pharmacogenomic variant data in the electronic medical records of more than 15,000 Vanderbilt patients.
Dr. Roden has received the Leon I. Goldberg Young Investigator Award and the Rawls-Palmer Progress in Science Award from the American Society for Clinical Pharmacology and Therapeutics, the Distinguished Scientist Award and the Douglas P. Zipes Lectureship Award from the Heart Rhythm Society, and the Distinguished Scientists award from the American Heart Association. He currently serves on the Science Board of the Food and Drug Administration.
Dr. Roden has been elected to membership in The American Society for Clinical Investigation and the Association of American Physicians, and fellowship in the American Association for the Advancement of Science.
Apostolia-Maria Tsimberidou, M.D., Ph.D.
Associate Professor, The University of Texas MD Anderson Cancer Center
Dr. Tsimberidou has pioneered the personalized medicine program in the Department of Investigational Cancer Therapeutics at MD Anderson Cancer Center.
In 2007, she designed and is the principal investigator of the Initiative for Molecular Profiling in Advanced Cancer Therapy (IMPACT) Trial, and she established a tissue bank with blood and tissue from patients with advanced cancer. She is committed to conducting research to improve the clinical outcomes of patients with cancer using the "precision" medicine approach.
Since joining MD Anderson in 1998, Dr. Tsimberidou has rigorously pursued a leading role in cancer research. In addition to laboratory research and patient care, she has diligently designed more than 20 clinical trials, including a study of oxaliplatin, fludarabine, cytarabine and rituximab, which has changed the standard of care for patients with Richter's syndrome.
Dr. Tsimberidou has published more than 175 papers (more than 110 as first or senior author), three book chapters and educational modules. She has received awards from the American Society of Clinical Oncology (ASCO), including a Career Development Award, as well as from the American Society of Hematology (ASH) and European Hematology Association (EHA).
Because of her innovative work, she has been invited as a keynote speaker at ASCO, ASH, EHA, the International Lymphoma Conference and the International Cardioncology Society. She completed the ASCO Leadership Development Program, and she serves on ASCO's Educational Committee and Cancer Research Committee.
Dr. Tsimberidou's work on personalized medicine demonstrated that identifying tumor-specific molecular aberrations and choosing therapy based on these abnormalities is associated with higher rates of response, survival and time to treatment failure in patients with advanced cancer compared with the standard approach.
She presented these results at the ASCO's Clinical Science Symposium: Personalized Medicine and at ASCO's prestigious inaugural official press program, which garnered extensive media coverage, including articles in The Economist, The Wall Street Journal, The Boston Globe and The Bloomberg Report.
Richard Weinshilboum, M.D.
Consultant, Department of Molecular Pharmacology and Experimental Therapeutics, Mayo Clinic
Dr. Weinshilboum joined the staff of Mayo Clinic in Rochester, Minn., in 1972 after earning his M.D. degree at the University of Kansas School of Medicine. He completed residency training in internal medicine at Massachusetts General Hospital — a Harvard teaching hospital — and a postdoctoral research fellowship at the National Institutes of Health in the laboratory of Nobel laureate Julius Axelrod.
Dr. Weinshilboum holds the academic rank of professor of medicine and pharmacology at Mayo Clinic College of Medicine and is recognized with the distinction of a named professorship, the Mary Lou and John H. Dasburg Professor of Cancer Genomics.
Dr. Weinshilboum is recognized as an internationally renowned medical investigator, with more than 350 peer-reviewed articles and chapters and many awards and recognitions, including the Mayo Distinguished Investigator and Distinguished Educator awards.
His research has focused on pharmacogenetics and pharmacogenomics, a science that studies the role of inheritance in individual variation in response to drugs. His studies have resulted in the discovery and characterization of a series of functionally and clinically important genetic polymorphisms (variations in DNA sequence involved in drug, neurotransmitter and hormone metabolism), the functional characterization of these common genetic polymorphisms, and the rapid translation of that information into clinical studies designed to test hypotheses with regard to individual variation in drug response or disease pathophysiology.
This research has also made it possible to develop molecular tests that help protect patients from life-threatening, genetically mediated adverse drug reactions.
Dr. Weinshilboum has chaired the Pharmacogenomics Research Network, a National Institutes of Health-funded initiative that includes scientists from Mayo Clinic, Harvard University and Stanford University, among others. This group of network scientists performs collaborative studies of the role of inheritance in variation in drug response.
He is past member of the advisory councils for the National Institute of General Medical Sciences and the National Human Genome Research Institute, the sponsor of the Human Genome Project.
Kelly K. Wix, Pharm.D., R.Ph.
Pharmacist Informaticist, Mayo Clinic
Dr. Wix has served as a clinical pharmacist at Mayo Clinic in Rochester, Minn., for more than 20 years. She is a Board Certified Pharmacotherapy Specialist and a Certified Professional in Healthcare Information and Management Systems. Her additional certifications include Medication Therapy Management and Mayo Quality Fellows Program (Silver). She holds an academic appointment as an instructor in pharmacy at Mayo Clinic College of Medicine.
Her experience encompasses several inpatient and outpatient practice areas. Roles she has fulfilled at Mayo Clinic include dispensing pharmacist (outpatient and inpatient), inpatient clinical and rounding pharmacist, pharmacotherapy coordinator (managerial), medication therapy management provider, outpatient clinic care team member, and informaticist.
Through these roles, Dr. Wix has worked with a wide variety of committees, workgroups, and electronic applications, tools and programs. She has a strong interest in medication safety, quality improvement, standardization, and data governance and integrity.
Most recently, Dr. Wix's experience with safe use of medications, ordering processes and electronic ordering tools is being utilized as a member of a team implementing clinical decision support for medications at the point of patient care. Delivering accurate and clinically actionable pharmacogenomics information at the point of medication order entry is a novel component of her work.